Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

Autor: Rugo, H.S., Oliveira, M., Howell, S.J., Dalenc, F., Cortes, J., Gomez, H.L., Hu, X., Jhaveri, K.L., Krivorotko, P., Loibl, S., Morales Murillo, S., Nowecki, Z., Okera, M., Park, Y.H., Sohn, J., Toi, M., Iwata, H., Yousef, S., Zhukova, L., Logan, J., Twomey, K., Khatun, M., D’Cruz, C.M., Turner, N.C.

Publikováno v: In ESMO Open September 2024 9(9)

The System Theory on the Integrity and Emergence of Design Object Images: a Preformal Study of Visual Cognitive Dynamic Information Systems at the Planning Stage / Zhukov V. L., Zhukova L. T., Smirnova A. M

Раздел 1. Теория и история дизайна = Section 1. Theory and history of design Рассмотрены определённые положения теории систем, организации, холизма, гештал

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1594::6512b5959b96313d885d4e89335ad17a
http://elib.bsu.by/handle/123456789/211727

Optical properties of single crystals and ceramics based on silver and thallium (I) halides in the range of 0.3–30.0 THz

Autor: Pestereva, P., Yuzhakova, A., Lvov, A., Salimgareev, D., Yudin, N., Voevodin, V., Sarkisov, S., Korsakov, A., Zhukova, L.

Publikováno v: In Infrared Physics and Technology September 2023 133

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.

Autor: Macarulla T; Vall d'Hebron University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain., Ren Z; Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China., Chon HJ; CHA Bundang Medical Center, Seongnam-Si, South Korea., Park JO; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kim JW; Seoul National University Bundang Hospital, Seongnam, South Korea., Pressiani T; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Li D; City of Hope National Comprehensive Cancer Center, Duarte, CA., Zhukova L; SBIH 'Moscow Clinical Scientific and Practical Center Named After A.S. Loginov' DHM, Moscow, Russian Federation., Zhu AX; Jiahui International Cancer Center, Jiahui Health, Shanghai, China., Chen MH; Taipei Veterans General Hospital, Taipei, Taiwan., Hack SP; Genentech Inc, South San Francisco, CA., Wu S; Genentech Inc, South San Francisco, CA., Liu B; Genentech Inc, South San Francisco, CA., Guan X; Genentech Inc, South San Francisco, CA., Lu S; Genentech Inc, South San Francisco, CA., Wang Y; Genentech Inc, South San Francisco, CA., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 18, pp. JCO2400337. Date of Electronic Publication: 2024 Oct 18.

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

Autor: Turner NC; Royal Marsden Hospital, Institute of Cancer Research, London, UK., Oliveira M; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Howell SJ; The Christie NHS Foundation Trust, Manchester, UK., Dalenc F; Oncopole Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France., Cortés J; Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.; Universidad Europea de Madrid, Faculty of Biomedical & Health Sciences, Department of Medicine, Madrid, Spain., Gomez HL; Instituto Nacional de Enfermedades Neoplásicas (INEN), Departamento de Oncología Médica, Lima, Peru.; Universidad Ricardo Palma, Lima, Peru., Hu X; Department of Breast Cancer & Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Jhaveri K; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Krivorotko P; N.N. Petrov National Medical Research Institute of Oncology, St. Petersburg, Russia., Loibl S; German Breast Group, Forschungs, Germany, Neu-Isenburg Centre for Haematology & Oncology, Bethanien, Frankfurt, Germany., Murillo SM; Institut de Recerca Biomèdica, Barcelona, Spain., Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Sohn JH; Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea., Toi M; Kyoto University Hospital, Kyoto, Japan., Tokunaga E; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Yousef S; Emek Medical Center, Afula, Israel., Zhukova L; Loginov Moscow Clinical Scientific Center, Moscow, Russia., Bruin E; Oncology R&D, AstraZeneca, Cambridge, UK., Grinsted L; Oncology R&D, AstraZeneca, Cambridge, UK., Schiavon G; Oncology R&D, AstraZeneca, Cambridge, UK., Foxley A; Oncology R&D, AstraZeneca, Cambridge, UK., Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

Publikováno v: Future oncology (London, England) [Future Oncol] 2024 Sep 16, pp. 1-13. Date of Electronic Publication: 2024 Sep 16.